OBJECTIVE: To evaluate the safety and efficacy of the @entity9618 procedure in @entity1 with genuine @entity3142 . METHODS: We conducted a prospective multicenter trial of a suprapubic approach to suburethral @entity7502 ( @entity9618 ) taping for the treatment of genuine @entity3142 . Between June 2001 and June 2002, 104 consecutive @entity1 (mean age 58.7 years) underwent @entity9618 in three centers. All the @entity1 had @entity6369 preoperatively. Detrusor instability was ruled out by cystometry. The @entity1 were evaluated 1, 3, 6 and 12 months postoperatively. The objective cure rate was evaluated by clinical and urodynamic examination, and the subjective cure rate was assessed using the Kings and Bristol questionnaire. RESULTS: The mean follow-up time was 11.9+/-1.9 months (range 8 to 20 months). The mean operating time was 30 min (25-50 min). Most of the @entity1 received general anesthesia (48%). The overall complication rate was 44.2% (46/104). The perioperative complication rate was 10.5%, including 11 @entity1494 . A significant difference in the @entity1494 rate was observed between @entity1 with and without previous @entity322 surgery (respectively 4/11, 36.3% versus 7/93, 7.5%; p<0.001). No @entity548 occurred. The early postoperative complication rate was 22.1%. The main complication was @entity74 (11 @entity1 ), which necessitated intermittent self-catheterization for less than 15 days (1.3+/-1.1 days, range 1 to 10 days). The late postoperative complication rate was 11.5%, including de novo urge symptoms in 12 @entity1 . The objective cure rate was 90.4%. No difference was found between @entity1 with genuine stress @entity322 and those with mixed @entity322 . The subjective cure rate was 72%. The objective and subjective cure rates differed significantly (p<0.05). The subjective cure rate among @entity1 with de novo urge symptoms was 58%. CONCLUSION: The @entity9618 procedure is a safe and effective treatment for @entity1 with @entity3142 , despite a high incidence of de novo urge symptoms.

A French multicenter clinical trial of @entity9618 for XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity9618 :: ('6678', 'Gene') :: ['SPARC'] @entity6369 :: ('MESH:D014526', 'Disease') :: ['urethral hypermobility'] @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder injury', 'bladder injuries'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhaging'] @entity7502 :: ('MESH:D011126', 'Chemical') :: ['polypropylene'] @entity74 :: ('MESH:D030342', 'Disease') :: ['voiding disorders'] @entity3142 :: ('MESH:D014550', 'Disease') :: ['stress urinary incontinence']
@entity3142 :: (MESH:D014550,Disease) :: ['stress urinary incontinence']
